S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Stilgenbauer, S.; Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S. M.; Brown, J. R.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
    Meeting Abstract

    Düll, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory vs early relapsed large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Glass, B.; Nastoupil, L.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López-Guillermo, A.; Martínez-López, J.; Novak, U.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the phase 3 MAIA study
    Meeting Abstract

    Kumar, S. K.; Moreau, P.; Bahlis, N.; Facon, T.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Hutchings, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional progression-free survival (cPFS)
    Meeting Abstract

    Braicu, E.; González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Freyer, G.; Backes, F. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors: analyses from INVICTUS
    Meeting Abstract

    Bauer, S.; Heinrich, M. C.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save